key: cord-0846395-vblrslnh authors: Li, Xue-Ting; Zhang, Mi-Wen; Zhang, Zhen-Zhou; Cao, Yu-Dan; Liu, Xiao-Yan; Miao, Ran; Xu, Yuan; Song, Xiao-Fang; Song, Jia-Wei; Liu, Ying; Xu, Ying-Le; Li, Jing; Dong, Ying; Zhong, Jiu-Chang title: Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19 date: 2021-05-15 journal: Int J Cardiol DOI: 10.1016/j.ijcard.2021.05.029 sha: e1b6740de4ef7edb260b731cd28b4fb836bbbd04 doc_id: 846395 cord_uid: vblrslnh BACKGROUND: Angiotensin converting enzyme 2 (ACE2) has recently been identified as the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent response for novel coronavirus disease 2019 (COVID-19). This study aimed to explore the roles of ACE2, apelin and sodium-glucose cotransporter 2 (SGLT2) in SARS-CoV-2-mediated cardiorenal damage. METHODS AND RESULTS: The published RNA-sequencing datasets of cardiomyocytes infected with SARS-CoV-2 and COVID-19 patients were used. String, UMAP plots and single cell RNA sequencing data were analyzed to show the close relationship and distinct cardiorenal distribution patterns of ACE2, apelin and SGLT2. Intriguingly, there were decreases in ACE2 and apelin expression as well as marked increases in SGLT2 and endothelin-1 levels in SARS-CoV-2-infected cardiomyocytes, animal models with diabetes, acute kidney injury, heart failure and COVID-19 patients. These changes were linked with downregulated levels of interleukin (IL)-10, superoxide dismutase 2 and catalase as well as upregulated expression of profibrotic genes and pro-inflammatory cytokines/chemokines. Genetic ACE2 deletion resulted in upregulation of pro-inflammatory cytokines containing IL-1β, IL-6, IL-17 and tumor necrosis factor α. More importantly, dapagliflozin strikingly alleviated cardiorenal fibrosis in diabetic db/db mice by suppressing SGLT2 levels and potentiating the apelin-ACE2 signaling. CONCLUSION: Downregulation of apelin and ACE2 and upregulation of SGLT2, endothelin-1 and pro-inflammatory cytokines contribute to SARS-CoV-2-mediated cardiorenal injury, indicating that the apelin-ACE2 signaling and SGLT2 inhibitors are potential therapeutic targets for COVID-19 patients. Coronavirus disease 2019 which was induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide devastating pandemic, with 137,571,000 cases as well as 2,962,000 deaths as of April 14th, 2021. Patients with pre-existing hypertension, diabetes mellitus (DM), heart failure (HF) were prone to be infected with SARS-CoV-2 and more likely to develop severe symptoms [1] . As SARS-CoV-2 had remarkable tropism for the heart and kidney, cardiorenal injury were evidenced as common complications in COVID-19 with poor prognosis [2, 3] . According to an observational, retrospective study of patients with confirmed COVID-19 infection, the mortality of patients developed acute heart failure was 46.8%, which was significantly higher than 19 .7% of the others [4] . In addition, the in-hospital mortality in COVID-19 patients with acute kidney injury (AKI) was 45% in comparison with the mortality of 7% in those without AKI [5] . Currently, the pathophysiological mechanisms of cardiorenal injury involved in COVID-19 remain largely unknown. Therefore, it's of great significance to find potential therapeutic targets for COVID-19. among COVID-19 patients [6] [7] [8] . Notably, protective effects of recombinant human ACE2 (rhACE2) were shown in acute lung injury, post-myocardial infarction (MI)-induced HF and hypertensive kidney injury [6, [8] [9] [10] . Besides, apelin, a positive regulator of ACE2, has been demonstrated as a negative regulator of the Ang II-AT1R pathway during hypertension and HF [6, 8, 11] . Thus, targeting apelin-ACE2 signaling may be promising therapeutic targets for SARS-CoV-2-mediated cardiorenal dysfunction. However, the exact effects of apelin-ACE2 signaling in COVID-19 remain to be further elucidated. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce body mass and systolic blood pressure levels and improve endothelial dysfunction beyond glycemic control [12] . Moreover, dapagliflozin has been demonstrated its therapeutic effects on various cardiovascular and renal diseases [13] . This study aimed to evaluate the effects of SARS-CoV-2 infection and dapagliflozin therapy on the apelin, ACE2 and SGLT2 signaling as well cardiorenal fibrotic injury during diabetes, HF and COVID-19 status. We also explored the published RNA-sequencing (RNA-seq) datasets of cardiomyocytes (CMs) infected with SARS-CoV-2, COVID-19 patients and animals with different disease conditions containing MI-HF, AKI and diabetes, providing potential therapeutic targets for SARS-CoV-2-mediated cardiorenal injury. Detailed methods are available in the online supplemental section. The raw gene counts data of adult human CMs and human embryonic stem cell J o u r n a l P r e -p r o o f Journal Pre-proof (hESC)-derived CMs infected with SARS-CoV-2 and mock was downloaded from the GEO repository database under the series number GSE151879 [14] . The normalized counts data for RNA-seq of isolated monocytes from peripheral blood of 6 COVID-19 patients and 3 healthy controls were available with accession number GSE160351 [15] . The normalized reads counts data for RNA-seq of buffy coat samples from COVID19+ and COVID19− critically ill patients were accessed from GSE154998 [16] . In addition, GEO Datasets SOFT files were available from https://www.ncbi.nlm.nih.gov/gds. The heart data of post-MI HF rats was from GDS4907, and the kidney data of AKI mice was from GDS4864. In addition, we used the protein and RNA expression data of ACE2, SGLT2 and apelin in different human tissues, and related single cell RNA-seq (scRNA-seq) gene expression data in kidney and heart through the Human Protein Atlas (HPA) (http://www.proteinatlas.org/). Furthermore, the protein-protein interaction (PPI) networks among ACE2, apelin and SGLT2 were obtained from the String database (https://string-db.org/). We analyzed the RNA-seq datasets to explore the changes of ACE2, endothelin-1 (ET-1), Heatmap analysis revealed the differentially expressed genes containing pro-inflammatory cytokines, chemokines, oxidative stress-and fibrosis-related genes in adult human CMs infected with SARS-CoV-2 ( We next evaluated the expression of ACE2 and apelin in the context of cardiorenal injury. In the hearts of post-MI HF rats, there were a significant decrease in apelin and marked elevations in ET-1, NOX4 and pro-inflammatory factors containing IL-18, MCP-1, CXCL16 ( Fig. 2A and 2B) . Moreover, levels of fibrosis-related genes including TGF-β1, MMP-2, CTGF, COL1A1 and COL3A1 were obviously increased in the hearts of post-MI HF rats (Fig. 2B ). We further infer that both ACE2 and apelin exhibited a downregulated tendency in the kidneys of AKI mice by RNA-seq datasets analysis (Fig. 2C) . Importantly, elevated expression of ET-1, IL-1β, IL-6, caspase 3, MCP-1, CXCR4, and CTGF were shown in AKI kidneys linked with decreased catalase and SOD2 (Fig. 2D) . Cytokine protein arrays demonstrated that dapagliflozin exerts cardiorenal protective effects by activating the apelin-ACE2 signaling and preventing the SGLT2 pathway, implying potential therapeutic targets of SGLT2 inhibitors for COVID-19-mediated cardiorenal injury (Fig. 4) . COVID-19 has a high prevalence among aged patients with or without comorbidities such as diabetes, HF and kidney failure [6] . ACE2 is located on the X chromosome and largely expressed in organs mainly targeted and damaged by SARS-CoV-2 [17] . Downregulation of ACE2 and the subsequent decreased Ang-(1-7)/Ang II ratio caused by SARS-CoV-2 infection play an essential role in COVID-19 associated cardiorenal dysfunction. Notably, circulating Ang II levels in SARS-CoV-2-infected patients were significantly increased and strongly associated with viral load and lung injury [18] . The vast release of cytokines in response to the viral infection resulted in a cytokine storm, subsequently leading to multiorgan dysfunction [19] . In this work, we demonstrated that there was a decrease in ACE2 expression and elevated levels of pro-inflammatory cytokines and chemokines in SARS-CoV-2-infected CMs and COVID-19 patients, suggesting that SARS-CoV-2-induced ACE2 downregulation were the primary mechanisms of organ injury during COVID-19. In subjects with higher ACE2 and lower ACE/ACE2 ratios, it appears that they are protected against COVID-19 exacerbation. Notably, sex differences in COVID-19 patients are emerging in terms of case fatality. The mortality rate among confirmed cases is lower in women than that in men, and the ACE/ACE2 activity ratio in females is lower than that in the male serum [17, 20] , indicating more susceptible for men to SARS-CoV-2 infection. Moreover, multiple pathological conditions, especially those of the cardiovascular system, are also characterized with a downregulation of ACE2 and elevated ACE/ACE2 ratio. Our previous published work demonstrated that Ang II-induced inflammation, oxidative stress, cardiorenal fibrotic remodeling and dysfunction were exacerbated in ACE2-deficient mice [21, 22] . Besides, apelin has been demonstrated to protect against acute respiratory distress syndrome, cardiovascular injury and endothelial inflammation through activating the ACE2/Ang-(1-7)/Mas axis and blocking the Ang II-AT1R actions, indicating that apelin/ACE2 signaling could be a promising therapeutic target in ameliorating cardiorenal J o u r n a l P r e -p r o o f Journal Pre-proof injuries during COVID-19 [23] . In this study, we demonstrated decreased apelin-ACE2 signaling and increased levels of pro-inflammatory factors and fibrosis-related genes in post-MI HF rats, AKI and ACE2 KO mice. The results implied that the cardiorenal injuries caused by SARS-CoV-2 could be exacerbated by decreasing of the apelin-ACE2 signaling. A high-glucose diet contributed to the augmentation of ACE/ACE2 ratio in the heart [17] , the subsequent imbalance of the Ang-(1-7)/Ang II was assumed to be the major contributor to progressively worsened systemic manifestations of COVID-19. Consistently, we revealed, for the first time, that both apelin and ACE2 were downregulated in heart and kidney of diabetic db/db mice, leading to exacerbated cardiorenal fibrosis. SGLT2 inhibitors, although originally developed as antidiabetic drugs, have exhibited dramatically effects of reducing cardiovascular mortality and hospitalization for HF and decelerating progression of chronic kidney disease event in absence of diabetes [24] . Beyond improving glycemic control, early natriuresis with a reduction in plasma volume, mitigating endothelial damage, improving mitochondrial function and myocardial efficiency, a reduction in systolic blood pressure levels and changes in tissue sodium handling are all likely to be the benefits of SGLT2 inhibitors [13] , all of which have been proposed as plausible mechanisms of cardiorenal protection in COVID-19 patients. More importantly, we found that dapagliflozin treatment potentiated the expression of apelin and ACE2, contributing to the alleviation of cardiorenal fibrosis and injury. Intriguingly, it was demonstrated that recombinant human soluble ACE2 (rhsACE2) could inhibit SARS-CoV-2 infection of Vero-E6 cells and human capillary and kidney organoids in a dose dependent manner [25] . Thus, it was postulated that exogenous supplement of rhsACE2 may J o u r n a l P r e -p r o o f Journal Pre-proof be a potential therapeutic approach for the administration of COVID-19. Given its cardiorenal protective effects, SGLT2 inhibitors are thought to be of potential significance for ameliorating cardiorenal dysfunction in COVID-19. Further studies are needed to explore whether SGLT2 inhibitors could be safely applied in patients with COVID-19. Downregulation of ACE2 mediated by SARS-CoV-2 infection and the subsequent exacerbated inflammation, oxidative stress, endothelial damage and fibrosis are responsible for adverse cardiorenal injury of COVID-19 patients. In the present study, we found marked decreases in apelin and ACE2 expression and significant increases in SGLT2, ET-1, pro-inflammatory factors in post-MI HF rats, AKI and diabetic mice. More importantly, we determined, for the first time, that dapagliflozin had a protective effect against the cardiorenal injury through improving the abnormal apelin-ACE2 signaling, indicating that the apelin-ACE2 signaling and SGLT2 inhibitors could be potential therapeutic targets for COVID-19. Further pre-clinical and clinical studies aimed to explore the potential therapeutic effects of SGLT2 inhibitors in COVID-19 need to be conducted. and the kidney between AKI mice and control group (C and D). n=3−6. Heatmap analysis and the relative protein levels of renal pro-inflammatory cytokines and chemokines between ACE2KO and WT mice (E and F). n=3. * P < 0.05, ** P < 0.01, *** P < 0.001 versus sham or control or WT group. ACE2 could catalyze Ang II conversion to Ang-(1-7), which exerts its cardiorenal protective effects including anti-inflammation, antioxidant and antifibrosis (marked in green). Dapagliflozin has a protective effect against the cardiorenal injury through improving the abnormal apelin-ACE2 signaling, indicating that SGLT2 inhibitors, apelin and rhACE2 could be potential therapeutic approachs in COVID-19 patients with adverse cardiorenal injury. Myocardial injury and COVID-19: Possible mechanisms Multiorgan and Renal Tropism of SARS-CoV-2 COVID-19 can affect the heart Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications Nephrology and COVID-19 SARS-CoV-2 Receptor and Regulator of the Celebrating the 20th Anniversary of the Discovery of ACE2 COVID-19, Renin-Angiotensin System and Endothelial Dysfunction Apelin Is a Negative Regulator of Angiotensin II-Mediated Adverse Myocardial Remodeling and Dysfunction Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19 The Elabela-APJ axis: a promising J o u r n a l P r e -p r o o f Journal Pre-proof therapeutic target for heart failure Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review SARS-CoV-2 Infected Cardiomyocytes Recruit Monocytes by Secreting CCL2 Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 Transcriptional profiling of leukocytes in critically ill COVID19 patients: implications for interferon response and coagulation A Key Also in 2019 Coronavirus Disease (Covid-19)?, Front. Med (Lausanne) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Cytokine storm and COVID-19: a J o u r n a l P r e -p r o o f Journal Pre-proof chronicle of pro-inflammatory cytokines Sex-related differences in COVID-19 lethality Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling Apelin-potential therapy for COVID-19? Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble All authors declare that they have no conflicts of interest. All authors declare that they have no conflicts of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.